Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
BMC Cancer|May 9, 2026
Proclarix' performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish populationRalph Schiess, Alcibiade Athanasiou, Madlen M E Kasten, et al.
Cancers|June 13, 2025
A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsNorma A Palma, Aimee L Lucas, Bryson W Katona, et al.
BJUI Compass|February 19, 2024
Evaluation of Proclarix in the diagnostic work-up of prostate cancerBasil Kaufmann, Sharon Fischer, Alcibiade Athanasiou, et al.
Proteomics|February 10, 2012
PASSEL: the PeptideAtlas SRMexperiment libraryTerry Farrah, Eric W Deutsch, Richard Kreisberg, et al.
Molecular & Cellular Proteomics : MCP|February 15, 2013
N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applicationsRuth Hüttenhain, Silvia Surinova, Reto Ossola, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.
European Urology Oncology|January 10, 2021
PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate CancerThomas Steuber, Isabel Heidegger, Mona Kafka, et al.
Cell Reports|May 31, 2018
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MSTatjana Sajic, Yansheng Liu, Eirini Arvaniti, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 9, 2011
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancerIgor Cima, Ralph Schiess, Peter Wild, et al.
European Urology|April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
Pageof 4